期刊文献+

电针“胃脘下俞穴”对T_2DM大鼠HPA轴的影响的实验研究 被引量:2

下载PDF
导出
摘要 目的:通过观察电针"胃脘下俞穴"对T2DM大鼠的干预效果,并进一步探讨HPA轴与T2DM的发病和治疗的确切关系,以期为针灸治疗糖尿病提供实验依据。方法:雄性Wistar大鼠随机抽出9只为空白组,喂以普通饲料。余下大鼠用高脂高糖饲料喂养4周后,采用链脲佐菌素(STZ)按35mg/kg.BW剂量腹腔注射诱导T2DM大鼠模型,将造模成功的大鼠分为模型组和电针胃脘下俞穴进行治疗。结果:与模型组相比,电针组大鼠空腹血糖值(FBG)显著下降(P<0.01),而模型组变化不大。电针组甘油三酯(TG)含量降低,但与空白组比较(P<0.05),差异无统计学意义;电针组高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白胆固醇(LDL-C),与模型组相比(P<0.05),差异无统计学意义。模型组大鼠CRH的含量较正常组极显著升高(P<0.01),电针组大鼠CRH、CORT的含量下降,与空白组和模型组比较有极显著差异(P<0.01)。结论:电针胃脘下俞穴可明显降低T2DM大鼠血糖及甘油三酯含量,并可有效的缓解HPA轴功能的亢进,可使CRH及CORT浓度降低。
出处 《陕西中医》 2014年第6期760-762,共3页 Shaanxi Journal of Traditional Chinese Medicine
基金 教育部科学技术研究重大项目(NO:313010)
  • 相关文献

参考文献9

二级参考文献28

共引文献86

同被引文献58

  • 1崔岱,刘超,唐伟,蒋琳,朱剑,刘翠萍.GLP-1对大鼠胰岛细胞增殖及凋亡的影响[J].中国糖尿病杂志,2007,15(5):310-312. 被引量:13
  • 2Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systamatic analysis of health examination surveys and epidemiological studies with 370 country - years and 2.7 million participants [ J ]. Lancet,2011,378:31 -40.
  • 3World Health Organization. Acupuncture:Review and Analysis of Re- ports on Controlled Clinical Trials[ M ]. Geneva:World Health Organi- zation, 2003.
  • 4Guariguata L,Whiting DR, Hambleton I, et al. Global, estimates of dia-betes prevalence for 2013 and projections for 2035 for the IDF diabe- tes atlas [ J ]. Diabetes Res Clin Praet,2014,103 (2) : 137 - 149.
  • 5Marre M, Shaw J, Brandle M, et al. LiraLiraglutide, a once - daily hu- man GLP - 1 analogue, added to a sulphonyluroa over 26 weeks pro- duces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD - 1 SU) [J]. Diabet Med,2009,26(3) :268 -278.
  • 6Nauek M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with met- formin,in type 2 diabetes: the LEAD ( liraglutide effect and action in diabetes) - 2 study[ J]. Diabetes Care ,2009,32 ( 1 ) :84 - 90.
  • 7Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes ( LEAD - 3 Mono) : a randomised, 52 - week, phase III, doubleblind, parallel - treatment trial [ J ]. Lan- cet,2009,373 (9662) :473 -481.
  • 8Zinman B, Gerieh J, Buse JB, et al. Efficacy and safety of the human glucagon - like peptide - 1 analog liraglutide in combination with met-formin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) [J]. Diabetes Care,2009,32(7) :1224 - 1230.
  • 9Russell -Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD -5 met + SU) :a random- ized controlled trial[ J]. Diabetologia ,2009,52 (10) :2046 - 2055.
  • 10Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus ex- enatide twice a day for type 2 diabetes : a 26 - week randomised, paral- lel - group, multinational, open - label trial ( LEAD - 6 ) [ J ]. Lancet, 2009,374 (9683) :39 - 47.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部